JP2022532430A5 - - Google Patents
Info
- Publication number
- JP2022532430A5 JP2022532430A5 JP2021568608A JP2021568608A JP2022532430A5 JP 2022532430 A5 JP2022532430 A5 JP 2022532430A5 JP 2021568608 A JP2021568608 A JP 2021568608A JP 2021568608 A JP2021568608 A JP 2021568608A JP 2022532430 A5 JP2022532430 A5 JP 2022532430A5
- Authority
- JP
- Japan
- Prior art keywords
- chimeric protein
- domain
- cancer
- ligand
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962848915P | 2019-05-16 | 2019-05-16 | |
| US62/848,915 | 2019-05-16 | ||
| PCT/US2020/033169 WO2020232365A1 (en) | 2019-05-16 | 2020-05-15 | Nk cell-directed chimeric proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022532430A JP2022532430A (ja) | 2022-07-14 |
| JP2022532430A5 true JP2022532430A5 (https=) | 2023-05-23 |
Family
ID=73289381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021568608A Pending JP2022532430A (ja) | 2019-05-16 | 2020-05-15 | Ｎｋ細胞指向性キメラタンパク質 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20200399344A1 (https=) |
| EP (1) | EP3969058A4 (https=) |
| JP (1) | JP2022532430A (https=) |
| CN (1) | CN114126663A (https=) |
| AU (1) | AU2020276296A1 (https=) |
| CA (1) | CA3140055A1 (https=) |
| WO (1) | WO2020232365A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024524301A (ja) * | 2021-07-02 | 2024-07-05 | ラエクナ セラピューティクス シャンハイ カンパニー リミテッド | 活性化肝星細胞（ｈｓｃ）の枯渇及びその使用 |
| CN114853905B (zh) * | 2022-04-14 | 2022-11-22 | 呈诺再生医学科技(珠海横琴新区)有限公司 | 一种基因修饰nk细胞与抗体联合使用治疗肿瘤方案 |
| WO2024073513A2 (en) * | 2022-09-27 | 2024-04-04 | Affini-T Therapeutics, Inc. | Chimeric receptors comprising interleukin 7 receptor (il7r) domains |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2035452B1 (en) * | 2006-06-22 | 2012-04-25 | Novo Nordisk A/S | Soluble heterodimeric receptors and uses thereof |
| WO2013112986A1 (en) * | 2012-01-27 | 2013-08-01 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
| JP6981973B2 (ja) * | 2015-10-01 | 2021-12-17 | ヒート バイオロジクス，インコーポレイテッド | Ｉ型及びｉｉ型細胞外ドメインを異種キメラタンパク質として連結する組成物及び方法 |
| BR112019005964A2 (pt) * | 2016-09-27 | 2019-06-18 | Epicentrx, Inc. | proteínas de fusão imunomoduladoras |
-
2020
- 2020-05-15 JP JP2021568608A patent/JP2022532430A/ja active Pending
- 2020-05-15 EP EP20805978.2A patent/EP3969058A4/en not_active Withdrawn
- 2020-05-15 CN CN202080051217.9A patent/CN114126663A/zh active Pending
- 2020-05-15 WO PCT/US2020/033169 patent/WO2020232365A1/en not_active Ceased
- 2020-05-15 AU AU2020276296A patent/AU2020276296A1/en not_active Abandoned
- 2020-05-15 CA CA3140055A patent/CA3140055A1/en active Pending
- 2020-09-10 US US17/017,117 patent/US20200399344A1/en not_active Abandoned
-
2022
- 2022-04-14 US US17/720,771 patent/US20230045794A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021202413B2 (en) | Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors | |
| JP2022532430A5 (https=) | ||
| CN109069638B (zh) | 用于癌症治疗的三特异性抑制剂 | |
| CN110337449B (zh) | 抗pd-l1抗体及其应用 | |
| CA3141626A1 (en) | Novel il-15 prodrugs and methods of use thereof | |
| JP2023145487A (ja) | 抗ｔｉｍ－３抗体のための投与レジメンおよびその使用 | |
| JP2018533371A5 (https=) | ||
| TW202323272A (zh) | 靶向flt3之嵌合抗原受體 | |
| US20220235134A1 (en) | Anti-b7-h3 antibodies | |
| JP2022512541A5 (https=) | ||
| JP2020502147A5 (https=) | ||
| CN113164538B (zh) | 修饰的溶瘤病毒、其组合物和用途 | |
| CA3198844A1 (en) | Novel anti-lilrb2 antibodies and derivative products | |
| JP2023543896A5 (https=) | ||
| JP2024525758A (ja) | がんのための併用療法におけるｃｄ４０およびｃｄ１３７に対する多重特異性結合剤 | |
| JP2022512539A5 (https=) | ||
| JP7689744B2 (ja) | 抗原特異的ｔ細胞応答を活性化するための材料および方法 | |
| WO2022254227A1 (en) | Treatment of pd-l1 negative or low expressing cancer with anti-icos antibodies | |
| US20250019411A1 (en) | T-Cell Engaging Polypeptides and Methods of Use Thereof | |
| JP2023554422A (ja) | がんの治療のための多重特異性抗体 | |
| WO2023138677A1 (en) | Novel anti-lag3 antibodies and derivative products | |
| AU2021207586A1 (en) | Method of treating a tumor with a combination of IL-7 protein and a bispecific antibody | |
| JP2022503621A5 (https=) | ||
| JP2023518835A (ja) | 制御性ｔ細胞の除去用の二重特異性融合タンパク質 | |
| WO2023143478A1 (en) | Novel anti-cd4 and anti-pd-l1 bispecific antibodies |